Patents by Inventor Marc Eloit
Marc Eloit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230151439Abstract: The invention relates to methods of diagnosis or detection of Moissiacense virus, a novel orthobunyavirus causing human encephalitis, comprising determining the presence of at least one nucleic acid or protein of said virus or antibodies thereto, in a biological sample. The invention also relates to the various diagnostic agents derived from the viral nucleic acids or proteins, in articular nucleic acid primers and probes, antigens and antibodies, and their use for the diagnosis of Moissiacense virus infection and associated disease, in particular encephalitis. The invention further relates to antigens derived from the viral proteins as vaccine for the prevention of Moissiacense virus infection and associated disease, in particular encephalitis.Type: ApplicationFiled: May 7, 2020Publication date: May 18, 2023Inventors: Marc ELOIT, Philippe PEROT, Danielle SEILHEAN, Charles DUYCKAERTS, Delphine CHRETIEN
-
Patent number: 11542563Abstract: A method for discriminating between live and dead microbes in a sample, by discriminating between transcriptionally-active and inert microbial nucleic acid sequences in the sample. In particular, the method is based on the comparison of levels of nucleotide substitution in a sample cultured in presence of an RNA-labelling agent. Also, a diagnosis method of microbial infections in a subject; and methods of assessing the risk of contamination of a sample, implementing the method for discriminating between live and dead microbes in a sample.Type: GrantFiled: October 20, 2020Date of Patent: January 3, 2023Assignee: PATHOQUESTInventors: Marc Eloit, Pascale Beurdeley, Stéphane Cruveiller
-
Patent number: 11530452Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: GrantFiled: September 3, 2020Date of Patent: December 20, 2022Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
-
Publication number: 20220205057Abstract: The present invention relates to a composition of primers for detecting HSIL comprising a first set of primers, called splice junctions set of primers which comprises at least 2 pairs of primers of each of a first subset of pairs of primers specific of HPV16, a second subset specific of HPV18, a third subset specific of HPV31, a fourth subset specific of HPV33, a fifth subset specific of HPV35, a sixth subset specific of HPV39, a seventh subset specific of HPV45, a eighth subset specific of HPV51, a ninth subset specific of HPV52, a tenth subset specific of HPV56, an eleventh subset specific of HPV58, a twelfth subset specific of HPV59 and a thirteenth subset specific of HPV66.Type: ApplicationFiled: March 16, 2020Publication date: June 30, 2022Inventors: Marc ELOIT, Philippe PEROT, Anne Emmanuelle Marie BITON
-
Publication number: 20210222261Abstract: A method for discriminating between live and dead microbes in a sample, by discriminating between transcriptionally-active and inert microbial nucleic acid sequences in the sample. In particular, the method is based on the comparison of levels of nucleotide substitution in a sample cultured in presence of an RNA-labelling agent. Also, a diagnosis method of microbial infections in a subject; and to methods of assessing the risk of contamination of a sample, implementing the method for discriminating between live and dead microbes in a sample.Type: ApplicationFiled: June 20, 2019Publication date: July 22, 2021Applicant: PATHOQUESTInventors: Marc ELOIT, Justine CHEVAL, Erika MUTH, Pascale BEURDELEY, Stéphane CRUVEILLER
-
Publication number: 20210087642Abstract: A method for discriminating between live and dead microbes in a sample, by discriminating between transcriptionally-active and inert microbial nucleic acid sequences in the sample. In particular, the method is based on the comparison of levels of nucleotide substitution in a sample cultured in presence of an RNA-labelling agent. Also, a diagnosis method of microbial infections in a subject; and methods of assessing the risk of contamination of a sample, implementing the method for discriminating between live and dead microbes in a sample.Type: ApplicationFiled: October 20, 2020Publication date: March 25, 2021Applicant: PATHOQUESTInventors: Marc ELOIT, Pascale BEURDELEY, Stéphane CRUVEILLER
-
Publication number: 20210032705Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: ApplicationFiled: September 3, 2020Publication date: February 4, 2021Inventors: Marc ELOIT, Nicolas TORNO, Jean DEREGNAUCOURT, Marion MOUTON, Isabelle HEARD, Philippe PEROT
-
Patent number: 10808284Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: GrantFiled: July 7, 2015Date of Patent: October 20, 2020Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHQUEST, L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARISInventors: Marc Eloit, Nicolas Torno, Jean Deregnaucourt, Marion Mouton, Isabelle Heard, Philippe Perot
-
Publication number: 20190085418Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: ApplicationFiled: November 30, 2018Publication date: March 21, 2019Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Patent number: 10144975Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: GrantFiled: April 19, 2013Date of Patent: December 4, 2018Assignees: INSTITUT PASTEUR, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Publication number: 20170107582Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.Type: ApplicationFiled: July 7, 2015Publication date: April 20, 2017Inventors: Marc ELOIT, Nicolas TORNO, Jean DEREGNAUCOURT, Marion MOUTON, Isabelle HEARD, Philippe PEROT
-
Patent number: 9403880Abstract: The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.Type: GrantFiled: November 25, 2011Date of Patent: August 2, 2016Assignees: INSTITUT PASTEUR, ECOLE NATIONALE VETERINAIRE D'ALFORT, PATHOQUESTInventors: Marc Eloit, Justine Cheval, Virginie Sauvage
-
Publication number: 20150132260Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.Type: ApplicationFiled: April 19, 2013Publication date: May 14, 2015Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
-
Publication number: 20140024017Abstract: The invention relates to the identification of a novel human polyomavirus species (designated IPPyV) and applications derived from the identified features and properties of this virus. The IPPy virus species of the invention qualifies as a human virus, in view of the fact that it is capable of infecting a human host. Having identified a novel human polyomavirus species, IPPyV, the inventors have been able to propose means for the detection of exposure or infection by such a virus, especially detection in a biological sample previously obtained from a human host. The invention also concerns means suitable for obtaining an immune response in a host with a view to prevent the onset or the development of an infection with an IPPyV.Type: ApplicationFiled: December 27, 2011Publication date: January 23, 2014Inventors: Marc Eloit, Justine Cheval, Virginie Sauvage
-
Publication number: 20130345400Abstract: The present invention relates to HGyV, a human gyrovirus related to the chicken anemia virus (CAV). The present invention also relates to a new proteins encoded by HGyV, which proteins display some homology to CAV proteins. Among these new proteins, H-apoptin is of particular interest as it is herein found for the first time in a human virus and can be used for treating cancer. Also provided are methods for detecting the HGyV virus in a subject.Type: ApplicationFiled: November 25, 2011Publication date: December 26, 2013Applicants: INSTITUT PASTEUR, PATHOQUEST, ECOLE NATIONALE VETERINAIRE D'ALFORTInventors: Marc Eloit, Justine Cheval, Virginie Sauvage, Vincent Foulongne
-
Patent number: 8119396Abstract: Recombinant adenoviruses or pseudoviruses having a deletion of all or part of the region of the adenovirus genome corresponding to nucleotides 311 to 499 in canine adenovirus type 2 (GeneBank J04368). Therapeutic methods of using the recombinant adenovirus or pseudovirus.Type: GrantFiled: October 8, 2003Date of Patent: February 21, 2012Assignees: Institut National de la Recherche Agronomique (INRA), Ecole Nationale Veterinaire d'AlfortInventors: Marc Eloit, Bernard Klonjkowski
-
Publication number: 20060233756Abstract: The invention relates to novel recombinant adenoviruses which can be obtained from a replicating adenovirus by deleting all or part of the region of the genome of said replicating adenovirus corresponding to that located in the genome of canine adenovirus type 2 (GenBank J04368) between positions 311 and 499, the aforementioned deletion comprising all or part of the region of the genome of the original replicating adenovirus corresponding to that located between positions 311 and 401 in the genome of canine adenovirus type 2. The invention also relates to the uses of said adenoviruses, particularly for therapeutic purposes.Type: ApplicationFiled: October 8, 2003Publication date: October 19, 2006Inventors: Marc Eloit, Bernard Klonjkowski
-
Patent number: 7109025Abstract: An in vivo replicative and recombined porcine adenovirus characterized in that it comprises a heterologous nucleotide sequence inserted into the porcine adenovirus in conditions enabling the latter to be replicated in vivo and to express the inserted heterologous nucleotide sequence, and in that the adenovirus genome comes from a 3 or 5 serotype (PAV-3 or PAV-5) adenovirus. Insertion occurs in a non-essential zone of the E3 region, preferably with deletion of said zone. The invention also relates to a recombined porcine vaccine comprising one such porcine adenovirus. The invention further relates to a serotype 3 or 5 porcine adenovirus vector that is replicative in vivo and is deleted in a non-essential region of the genome thereof. The invention also relates to a DNA fragment comprising all or part of the referenced SEQ ID NO.5 nucleotide sequence.Type: GrantFiled: February 8, 2000Date of Patent: September 19, 2006Assignees: Merial, Ecole Nationale Veterinaire de Maison AlfortInventors: Marc Eloit, Bernard Georges Klonjkowski
-
Publication number: 20050053622Abstract: The invention relates to a vaccine against coronavirus infections and, in particular, against feline infectious peritonitis (FIP). The inventive vaccine comprises immunogenic peptides included in the S protein of feline coronaviruses (FcoV), which do not result from immunologic enhancement. The invention also relates to the use of at least one peptide for the preparation of a vaccine that induces protection against coronavirus infections, said peptide being selected from the group comprising fragments of an S protein of coronavirus of at least 12 amino acids, included in the SEQ ID NO: 5, or nucleic acid fragments of at least 36 nucleotides, included in the SEQ ID NO: 10 and coding for one of said peptides.Type: ApplicationFiled: August 9, 2002Publication date: March 10, 2005Inventors: Andre Aubert, Veronique Duquesne, Marc Eloit, Valerie Gonon